Imperative Care
Imperative Care develops comprehensive stroke care solutions, from diagnosis to recovery, including its flagship Zoom Stroke System for clot removal.
Secondary Market Price
How Imperative Care Measures Up
To help you manage your Imperative Care equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series E
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Imperative Care's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Imperative Care Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Imperative Care's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Imperative Care is a medical technology company founded in 2015 and based in Campbell, California. The company researches, develops, and manufactures devices for people affected by vascular diseases such as stroke and pulmonary embolism. Its primary product is the Zoom Stroke System, a complete system designed for clot removal in patients with ischemic stroke. Imperative Care, which has raised $345 million in total funding, states it uses a physician-driven approach to innovate across the patient journey, from diagnosis and treatment to rehabilitation.
The company's forward-looking efforts are focused on accelerating the development of technologies to expand care for patients. At a recent medical conference, #SVIN25, the company presented findings on its ADAPT 2.0 technique using the Zoom Stroke System, which demonstrated a 97% rate of successful final reperfusion (mTICI ≥ 2b) and a median procedure time of 17 minutes. Additionally, a single-center retrospective study showed that its Zoom88 device provided comparable thrombectomy efficacy with a faster time to recanalization and a more favorable complication profile when compared to a commonly used balloon guide catheter.
- Ally Bridge Group
- D1 Capital Partners
- AMED Ventures
- Bain Capital Life Sciences
- Rock Springs Capital Management LP
- Innovatus Capital Partners, LLC
- Pura Vida Investments
- Catalio Capital Management, LP
- HealthCor Family Office
- Montreux Growth Partners
- INTAI Technology Corp
- Co-Founder, Fred Khosravi
- Co-Founder, L. Nelson (Nick) Hopkins
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Imperative Care worth joining?
Deciding to join a company like Imperative Care involves evaluating career opportunities, company culture, and the potential of its equity compensation. Tools like Prospect can help you analyze the financial side by forecasting your equity's potential value.
What should I do with my Imperative Care stock?
The right strategy for your Imperative Care stock depends on your personal financial situation, risk tolerance, and tax implications. Platforms like Prospect can build a personalized plan for you, helping you decide when to exercise options or sell shares to optimize your outcome.
Can you sell Imperative Care stock?
Selling stock in a private company like Imperative Care is often possible through company-approved liquidity events like tender offers or on secondary markets. Prospect's tools can help you navigate these sales by determining how much to sell and which shares are the most tax-optimal.
How can I find the value of my Imperative Care stock?
The value of private stock like Imperative Care's is typically determined by its latest 409A valuation and any recent secondary market transactions. You can use Prospect's predictive models, which are trained on VC data, to forecast the potential future value of your equity.
What is Imperative Care's equity worth?
The ultimate worth of your Imperative Care equity is uncertain and depends on the company's future success and an eventual liquidity event like an IPO or acquisition. To better understand the potential range of outcomes, you can use a platform like Prospect to model your equity's value based on various data points.
What is Imperative Care's stock ticker symbol?
As a private company, Imperative Care does not have a stock ticker symbol. Ticker symbols are only assigned to companies when they become publicly traded on a stock exchange.
Can I buy or sell Imperative Care stock?
As an employee, you can acquire stock by exercising your options, and selling is typically possible during specific liquidity events or on secondary markets. Prospect provides strategies to help you make tax-optimal decisions for both exercising options and selling shares.
What is the criteria to buy or invest in Imperative Care stock?
Investing in a private company is typically restricted to accredited investors during funding rounds, while employees acquire equity through their compensation packages. If you are an employee with equity, Prospect can help you manage your holdings and create a strategy for your options and shares.
